{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:47:59Z","timestamp":1792518479454,"version":"4.5.0"},"reference-count":150,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoporosis in men is under-recognized and under-treated despite a substantial disease burden and poorer fracture-related outcomes than in women. Secondary osteoporosis is highly prevalent in men, making the identification and management of underlying causes essential. BMD and fracture risk are influenced by sex-specific patterns of skeletal growth and age-related bone loss, with men typically exhibiting greater cortical thickness, larger bone size, and trabecular thinning rather than loss of trabecular number. Although randomized controlled trials in men are fewer than in postmenopausal women, bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab have all been shown to significantly increase BMD. Fracture outcome data remain limited; however, reductions in vertebral fracture risk have been demonstrated for zoledronate, alendronate, risedronate, denosumab, and teriparatide. Treatment should be individualized according to fracture risk, comorbidities, and patient preferences. In men at very high fracture risk, osteoanabolic therapy should be considered as first-line treatment, followed by antiresorptive therapy to consolidate and maintain BMD gains. Goal-directed (treat-to-target) management, including long-term maintenance therapy, and careful discontinuation strategies, particularly following denosumab, is essential for optimizing long-term skeletal health. This narrative review and position statement by The ECTS Clinical Action Group provides an updated overview of current and emerging treatment options and offers practical, evidence-based recommendations for the long-term management of osteoporosis in men.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag145","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:42:59Z","timestamp":1790941379000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of male osteoporosis: a narrative review and position statement by the ECTS Clinical Action Group"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-8128","authenticated-orcid":false,"given":"Anne Sophie","family":"S\u00f8lling","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-8623","authenticated-orcid":false,"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Lille , CHU Lille, MABlab ULR 4490, 59000 Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D","family":"Anastasilakis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 424 General Military Hospital , 56429 Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , 1023 Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P","family":"Yavropoulou","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, LAIKO University Hospital, Medical School, National and Kapodistrian University of Athens , 11527 Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-1957","authenticated-orcid":false,"given":"Barbara","family":"Hauser","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Unit, NHS Lothian, Western General Hospital , EH4 2XU Edinburgh ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-3381","authenticated-orcid":false,"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[{"name":"Unit of Osteometabolic and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-492X","authenticated-orcid":false,"given":"Suzanne N","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University , Montreal, H4A 3J1 Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-4408","authenticated-orcid":false,"given":"Jane","family":"Cauley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Pittsburgh , Pittsburgh, 15261 Pennsylvania ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6080","authenticated-orcid":false,"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Holb\u00e6k Hospital , 4300 Holb\u00e6k ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem F","family":"Lems","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam University Medical Centre , 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"4","key":"2026102013362750000_ref1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-based guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"2026102013362750000_ref2","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the global burden of disease study 2019","volume":"2","author":"GBD 2019 Fracture Collaborators","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026102013362750000_ref3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: a new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch Osteoporos"},{"issue":"7","key":"2026102013362750000_ref4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026102013362750000_ref5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026102013362750000_ref6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"2026102013362750000_ref7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ageing\/afr170","article-title":"Osteoporosis and vertebral fractures in men aged 60-74 years","volume":"41","author":"Frost","year":"2012","journal-title":"Age Ageing"},{"issue":"4","key":"2026102013362750000_ref8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026102013362750000_ref9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00198-023-07012-1","article-title":"A meta-analysis of previous falls and subsequent fracture risk in cohort studies","volume":"35","author":"Vandenput","year":"2024","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026102013362750000_ref10","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.3556","article-title":"Measures of physical performance and muscle strength as predictors of fracture risk independent of FRAX, falls, and aBMD: a meta-analysis of the osteoporotic fractures in men (MrOS) study","volume":"33","author":"Harvey","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026102013362750000_ref11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jbmr.2836","article-title":"Risk factors for hip fracture in older men: the osteoporotic fractures in men study (MrOS)","volume":"31","author":"Cauley","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026102013362750000_ref12","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","article-title":"Mortality rates after incident non-traumatic fractures in older men and women","volume":"22","author":"Morin","year":"2011","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026102013362750000_ref13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"key":"2026102013362750000_ref14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijotn.2018.11.007","article-title":"Men\u2019s perceptions of living with osteoporosis: a systematic review of qualitative studies","volume":"33","author":"Compton","year":"2019","journal-title":"Int J Orthop Trauma Nurs"},{"issue":"8","key":"2026102013362750000_ref15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00198-005-1950-0","article-title":"The near absence of osteoporosis treatment in older men with fractures","volume":"16","author":"Feldstein","year":"2005","journal-title":"Osteoporos Int"},{"issue":"7","key":"2026102013362750000_ref16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.eprac.2024.04.006","article-title":"Hormonal control of Bone architecture throughout the lifespan: implications for fracture prediction and prevention","volume":"30","author":"Grigoryan","year":"2024","journal-title":"Endocr Pract"},{"key":"2026102013362750000_ref17","doi-asserted-by":"publisher","first-page":"k3225","DOI":"10.1136\/bmj.k3225","article-title":"Assessment of the genetic and clinical determinants of fracture risk: genome wide association and Mendelian randomisation study","volume":"362","author":"Trajanoska","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"2026102013362750000_ref18","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1210\/jcem.86.10.7960","article-title":"Clinical review 137: sexual dimorphism in skeletal size, density, and strength","volume":"86","author":"Seeman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026102013362750000_ref19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1210\/jcem.83.5.4765","article-title":"Differential effect of race on the axial and appendicular skeletons of children","volume":"83","author":"Gilsanz","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026102013362750000_ref20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bone.2005.07.025","article-title":"Structural adaptations to bone loss in aging men and women","volume":"38","author":"Russo","year":"2006","journal-title":"Bone"},{"issue":"10","key":"2026102013362750000_ref21","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","article-title":"An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG)","volume":"32","author":"Kanis","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026102013362750000_ref22","doi-asserted-by":"publisher","first-page":"e76774","DOI":"10.7759\/cureus.76774","article-title":"The role of the periosteum in bone formation from adolescence to old age","volume":"17","author":"Panagakis","year":"2025","journal-title":"Cureus"},{"issue":"12","key":"2026102013362750000_ref23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1359\/JBMR.040916","article-title":"Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites","volume":"19","author":"Riggs","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026102013362750000_ref24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1359\/jbmr.2002.17.12.2222","article-title":"Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment","volume":"17","author":"Miller","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102013362750000_ref25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","article-title":"Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study","volume":"7","author":"Samelson","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026102013362750000_ref26","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/jbmr.2067","article-title":"Vertebral size, bone density, and strength in men and women matched for age and areal spine BMD","volume":"29","author":"Bruno","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102013362750000_ref27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-011-1822-8","article-title":"Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women","volume":"23","author":"Srinivasan","year":"2012","journal-title":"Osteoporos Int"},{"key":"2026102013362750000_ref28","doi-asserted-by":"publisher","first-page":"116803","DOI":"10.1016\/j.bone.2023.116803","article-title":"Sex disparities in tibia-fibula geometry and density are associated with elevated bone strain in females: a cross-validation study","volume":"173","author":"Bruce","year":"2023","journal-title":"Bone"},{"issue":"3","key":"2026102013362750000_ref29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s8756-3282(00)00342-2","article-title":"Stress fracture in military recruits: gender differences in muscle and bone susceptibility factors","volume":"27","author":"Beck","year":"2000","journal-title":"Bone"},{"issue":"2","key":"2026102013362750000_ref30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102013362750000_ref31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","article-title":"Osteoporosis in men","volume":"10","author":"Vilaca","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026102013362750000_ref32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s11154-022-09763-4","article-title":"Diagnosis of hypogonadism in ageing men","volume":"23","author":"Kaufman","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2026102013362750000_ref33","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jbmr.2817","article-title":"Age- and sex-related changes in Bone microarchitecture and estimated strength: a three-year prospective study using HRpQCT","volume":"31","author":"Shanbhogue","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00003086-198702000-00038","article-title":"The microanatomy of trabecular bone loss in normal aging men and women","volume":"215","author":"Aaron","year":"1987","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"2026102013362750000_ref35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1359\/jbmr.071020","article-title":"A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men","volume":"23","author":"Riggs","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026102013362750000_ref36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00223-001-1040-z","article-title":"During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone","volume":"69","author":"Seeman","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2026102013362750000_ref37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00198-025-07746-0","article-title":"Fracture trends in Denmark from 1997 to 2021","volume":"37","author":"Visker","year":"2026","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026102013362750000_ref38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1210\/er.2008-0002","article-title":"Osteoporosis in men","volume":"29","author":"Khosla","year":"2008","journal-title":"Endocr Rev"},{"issue":"1","key":"2026102013362750000_ref39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1210\/edrv-16-1-87","article-title":"Osteoporosis in men","volume":"16","author":"Orwoll","year":"1995","journal-title":"Endocr Rev"},{"issue":"3","key":"2026102013362750000_ref40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026102013362750000_ref41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1007\/s00198-003-1507-z","article-title":"The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture","volume":"14","author":"McLellan","year":"2003","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026102013362750000_ref42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr.21796","article-title":"Prevalence of oral glucocorticoid usage in the United States: a general population perspective","volume":"65","author":"Overman","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2026102013362750000_ref43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"issue":"11","key":"2026102013362750000_ref44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S2213-8587(25)00251-7","article-title":"Glucocorticoid-induced osteoporosis: novel concepts and clinical implications","volume":"13","author":"Hofbauer","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102013362750000_ref45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102013362750000_ref46","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"issue":"20","key":"2026102013362750000_ref47","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026102013362750000_ref48","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","article-title":"Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study","volume":"5","author":"Attard","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026102013362750000_ref49","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1210\/clinem\/dgab539","article-title":"Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis","volume":"106","author":"Ku","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026102013362750000_ref50","doi-asserted-by":"publisher","first-page":"105714","DOI":"10.1016\/j.jbspin.2024.105714","article-title":"Proton pump inhibitors, bone and phosphocalcic metabolism","volume":"91","author":"Philippoteaux","year":"2024","journal-title":"Joint Bone Spine"},{"issue":"2","key":"2026102013362750000_ref51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00223-009-9327-6","article-title":"Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson\u2019s disease","volume":"86","author":"Lee","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2026102013362750000_ref52","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00198-017-4171-4","article-title":"Adverse bone effects of medications used to treat non-skeletal disorders","volume":"28","author":"Watts","year":"2017","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026102013362750000_ref53","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/QAD.0000000000001067","article-title":"Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients","volume":"30","author":"Casado","year":"2016","journal-title":"AIDS"},{"issue":"10","key":"2026102013362750000_ref54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(24)00163-3","article-title":"Bone health in adults with obesity before and after interventions to promote weight loss","volume":"12","author":"Paccou","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026102013362750000_ref55","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/jbmr.2226","article-title":"Bone metabolism after bariatric surgery","volume":"29","author":"Yu","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102013362750000_ref56","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2026102013362750000_ref57","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.25011\/cim.v45i3.38875","article-title":"Denosumab versus bisphosphonates for the prevention of the vertebral fractures in men with osteoporosis: an updated network meta-analysis","volume":"45","author":"Li","year":"2022","journal-title":"Clin Invest Med"},{"issue":"11","key":"2026102013362750000_ref58","doi-asserted-by":"publisher","first-page":"e2141","DOI":"10.1210\/clinem\/dgae023","article-title":"Bisphosphonate use and risk of atypical femoral fractures: a Danish case-cohort study with blinded radiographic review","volume":"109","author":"Bauer","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026102013362750000_ref59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthop"},{"issue":"17","key":"2026102013362750000_ref60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14175988","article-title":"Prevalence of osteonecrosis of the jaw following tooth extraction in patients with osteoporosis: a systematic review and meta-analysis","volume":"14","author":"Kostares","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"2026102013362750000_ref61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00774-009-0136-9","article-title":"The effects of weekly alendronate therapy in Taiwanese males with osteoporosis","volume":"28","author":"Hwang","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2026102013362750000_ref62","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/PL00004182","article-title":"Effects of alendronate on bone density in men with primary and secondary osteoporosis","volume":"11","author":"Ho","year":"2000","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026102013362750000_ref63","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026102013362750000_ref64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2026102013362750000_ref65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"issue":"4","key":"2026102013362750000_ref66","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13685530701661051","article-title":"The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men","volume":"10","author":"Guven","year":"2007","journal-title":"Aging Male"},{"issue":"1","key":"2026102013362750000_ref67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1385\/jcd:8:1:007","article-title":"A systematic review of the effect of alendronate on bone mineral density in men","volume":"8","author":"Sawka","year":"2005","journal-title":"J Clin Densitom"},{"issue":"12","key":"2026102013362750000_ref68","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-005-1879-3","article-title":"Alendronate for osteoporosis in men with androgen-repleted hypogonadism","volume":"16","author":"Shimon","year":"2005","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026102013362750000_ref69","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clin Drug Investig"},{"issue":"9","key":"2026102013362750000_ref70","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"issue":"13","key":"2026102013362750000_ref71","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"2026102013362750000_ref72","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026102013362750000_ref73","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102013362750000_ref74","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2026102013362750000_ref75","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2026102013362750000_ref76","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5\u2009mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref77","doi-asserted-by":"publisher","first-page":"1666421","DOI":"10.3389\/fphar.2025.1666421","article-title":"Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"2026102013362750000_ref78","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jbmr.4802","article-title":"Effect of a three-day course of dexamethasone on acute phase response following treatment with Zoledronate: a randomized controlled trial","volume":"38","author":"Murdoch","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026102013362750000_ref79","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102013362750000_ref80","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bone.2012.06.016","article-title":"Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study","volume":"51","author":"Boonen","year":"2012","journal-title":"Bone"},{"issue":"5","key":"2026102013362750000_ref81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"issue":"3","key":"2026102013362750000_ref82","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"issue":"8","key":"2026102013362750000_ref83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2169\/internalmedicine.47.0591","article-title":"Efficacy of risedronate in Japanese male patients with primary osteoporosis","volume":"47","author":"Majima","year":"2008","journal-title":"Intern Med"},{"issue":"6","key":"2026102013362750000_ref84","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026102013362750000_ref85","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026102013362750000_ref86","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"issue":"4","key":"2026102013362750000_ref87","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"issue":"8","key":"2026102013362750000_ref88","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/BF03347354","article-title":"Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years","volume":"26","author":"Lamy","year":"2003","journal-title":"J Endocrinol Investig"},{"issue":"13","key":"2026102013362750000_ref89","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"issue":"23","key":"2026102013362750000_ref90","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026102013362750000_ref91","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6&lt;1444::aid-cncr1468&gt;3.0.co;2-m","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"2026102013362750000_ref92","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension","volume":"17","author":"Brumsen","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026102013362750000_ref93","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102013362750000_ref94","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026102013362750000_ref95","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jgs.19260","article-title":"Denosumab for osteoporosis in older adults in long-term care: a randomized trial","volume":"73","author":"Greenspan","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2026102013362750000_ref96","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3904\/kjim.2022.064","article-title":"The efficacy of denosumab in Korean male patients with osteoporosis","volume":"37","author":"Jeong","year":"2022","journal-title":"Korean J Intern Med"},{"issue":"1","key":"2026102013362750000_ref97","doi-asserted-by":"publisher","first-page":"22785","DOI":"10.1038\/s41598-024-73398-5","article-title":"Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study","volume":"14","author":"Kobayakawa","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"2026102013362750000_ref98","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00198-024-07381-1","article-title":"Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study","volume":"36","author":"Huang","year":"2025","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026102013362750000_ref99","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026102013362750000_ref100","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref101","first-page":"dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"756","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026102013362750000_ref102","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/JBMR.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026102013362750000_ref103","doi-asserted-by":"publisher","first-page":"e2443899","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026102013362750000_ref104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-025-01364-y","article-title":"Impact of zoledronic acid on bone mineral density and trabecular score following denosumab discontinuation in older adults in long-term care","volume":"116","author":"Haeri","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2026102013362750000_ref105","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026102013362750000_ref106","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026102013362750000_ref107","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3803\/EnM.2024.2227","article-title":"Effects of sequential anti-resorptive agents on bone mineral density following denosumab withdrawal: a multicenter real-world study in Korea (MAXCARE study)","volume":"40","author":"Ha","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"6","key":"2026102013362750000_ref108","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026102013362750000_ref109","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026102013362750000_ref110","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","article-title":"Clinical experience with denosumab discontinuation","volume":"36","author":"Laursen","year":"2025","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026102013362750000_ref111","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00198-022-06610-9","article-title":"Discontinuation of denosumab in men with prostate cancer","volume":"34","author":"S\u00f8lling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026102013362750000_ref112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102013362750000_ref113","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"issue":"9","key":"2026102013362750000_ref114","doi-asserted-by":"publisher","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"5","key":"2026102013362750000_ref115","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026102013362750000_ref116","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1210\/jcem.85.9.6818","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026102013362750000_ref117","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"issue":"6","key":"2026102013362750000_ref118","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref119","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone"},{"issue":"12","key":"2026102013362750000_ref120","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026102013362750000_ref121","doi-asserted-by":"publisher","first-page":"e4222","DOI":"10.1210\/clinem\/dgac486","article-title":"Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J study","volume":"107","author":"Matsumoto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026102013362750000_ref122","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"2026102013362750000_ref123","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026102013362750000_ref124","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1210\/clinem\/dgaf191","article-title":"Testosterone and male Bone health: a puzzle of interactions","volume":"110","author":"Tenuta","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026102013362750000_ref125","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1210\/jc.2009-0206","article-title":"The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men","volume":"94","author":"LeBlanc","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102013362750000_ref126","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric Bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2026102013362750000_ref127","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","article-title":"Testosterone treatment and fractures in men with hypogonadism","volume":"390","author":"Snyder","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102013362750000_ref128","doi-asserted-by":"publisher","first-page":"107854","DOI":"10.1016\/j.maturitas.2023.107854","article-title":"EMAS position statement: testosterone replacement therapy in older men","volume":"178","author":"Kanakis","year":"2023","journal-title":"Maturitas"},{"issue":"5","key":"2026102013362750000_ref129","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026102013362750000_ref130","doi-asserted-by":"publisher","first-page":"ziae146","DOI":"10.1093\/jbmrpl\/ziae146","article-title":"Cardiovascular outcomes of romosozumab treatment-real-world data analysis","volume":"9","author":"Tsur","year":"2024","journal-title":"JBMR Plus"},{"issue":"1","key":"2026102013362750000_ref131","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2026102013362750000_ref132","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","article-title":"Management of patients at very high risk of osteoporotic fractures through sequential treatments","volume":"34","author":"Curtis","year":"2022","journal-title":"Aging Clin Exp Res"},{"issue":"Suppl 1","key":"2026102013362750000_ref133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"2026102013362750000_ref134","doi-asserted-by":"publisher","first-page":"dgaa048","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026102013362750000_ref135","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1359\/jbmr.060708","article-title":"BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women","volume":"21","author":"Cummings","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026102013362750000_ref136","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1359\/jbmr.061017","article-title":"Predictors of non-spine fracture in elderly men: the MrOS study","volume":"22","author":"Lewis","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref137"},{"issue":"10","key":"2026102013362750000_ref138","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102013362750000_ref139","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent Zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102013362750000_ref140","doi-asserted-by":"publisher","first-page":"h4183","DOI":"10.1136\/bmj.h4183","article-title":"Calcium intake and bone mineral density: systematic review and meta-analysis","volume":"351","author":"Tai","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"2026102013362750000_ref141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-025-00904-7","article-title":"Calcium supplementation-efficacy and safety","volume":"23","author":"Reid","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2026102013362750000_ref142","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7326\/0003-4819-152-5-201003020-00010","article-title":"Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events","volume":"152","author":"Wang","year":"2010","journal-title":"Ann Intern Med"},{"issue":"18","key":"2026102013362750000_ref143","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"2026102013362750000_ref144","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1532-5415.2010.02861.x","article-title":"Longitudinal physical activity changes in older men in the osteoporotic fractures in men study","volume":"58","author":"Janney","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"2026102013362750000_ref145","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4008","article-title":"A comparison of bone-targeted exercise strategies to reduce fracture risk in middle-aged and older men with osteopenia and osteoporosis: LIFTMOR-M semi-randomized controlled trial","volume":"35","author":"Harding","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2026102013362750000_ref146","article-title":"The prostate cancer (PCa) guidelines panel","author":"E. A. of Urology","journal-title":"Prostate Cancer"},{"issue":"12","key":"2026102013362750000_ref147","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2026102013362750000_ref148","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"issue":"9","key":"2026102013362750000_ref149","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026102013362750000_ref150","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag145\/71626509\/zjag145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag145\/71626509\/zjag145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:36:33Z","timestamp":1792517793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article\/doi\/10.1093\/jbmr\/zjag145\/8868910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":150,"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag145","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"zjag145"}}